About Ascentage Pharma
Ascentage Pharma is a company based in Hong Kong (China) founded in 2009. Ascentage Pharma has raised $237.5 million across 3 funding rounds from investors including ArrowMark Partners, CTS Capital Advisors and Oriza Ventures. Ascentage Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Hong Kong, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$237.5 M (USD)
in 3 rounds
-
Latest Funding Round
$150 M (USD), Series C
Jul 17, 2018
-
Investors
ArrowMark Partners
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Ascentage Pharma
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Operations Team
7 people
Clinical Team
5 people
Scientific Team
3 people
Data Analysis and Operations Team
3 people
Legal and Compliance
2 people
Senior Team
2 people
Product Management Team
2 people
Unlock access to complete
Funding Insights of Ascentage Pharma
Ascentage Pharma has successfully raised a total of $237.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ascentage Pharma
Ascentage Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ArrowMark Partners, CTS Capital Advisors and Oriza Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
PE firm focused on medicine based companies
|
Locked | Locked | Locked | |
|
Private equity firm investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Ascentage Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ascentage Pharma
Investment portfolio details for Ascentage Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ascentage Pharma
Detailed financials for Ascentage Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ascentage Pharma Comparisons
Peer comparison for Ascentage Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ascentage Pharma
Ascentage Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Ascentage Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ascentage Pharma
Complete news archive for Ascentage Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascentage Pharma
Ascentage Pharma was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Ascentage Pharma is headquartered in Hong Kong, China.
Ascentage Pharma is a funded company, having raised a total of $237.5M across 3 funding rounds to date.
Ascentage Pharma was founded in 2009 in Hong Kong, China, where small molecule drugs targeting cancers are developed. The pipeline includes AT101 as a pan-Bcl-2 inhibitor for non-small cell lung cancer, HQP8361 as a c-Met inhibitor for solid tumors, APG-1387 as an IAP inhibitor for solid tumors, and HQP1351 as a Bcr-Abl kinase inhibitor for chronic myeloid leukemia. Key oncogenic drivers in human cancers are addressed by several preclinical programs.
Ascentage Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Ascentage Pharma has 11 investors. Key investors include ArrowMark Partners, CTS Capital Advisors, Oriza Ventures, CCB International, and Yuan Ming Capital.